Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-04
2009-12-29
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C424S184100, C424S190100, C424S234100
Reexamination Certificate
active
07638489
ABSTRACT:
The present invention relates toBartonella henselaeas a component of a pharmaceutical composition for the modulation of the angiogenesis; a nucleic acid molecule that is derived from the gene encoding theBartonella henselaeadhesin A protein (BadA), a vector comprising said nucleic acid molecule; a host containing said nucleic acid molecule or said vector; a (poly)peptide encoded by said nucleic acid molecule; a composition comprisingBartonella henselaebacteria; a composition comprising aforesaid (poly)peptide; a method for treating a human or animal being in need of the modulation of the angiogenesis, a method for detecting an infection byBartonellain a human or animal being, as well as a method for immunizing a cat.
REFERENCES:
patent: 6406887 (2002-06-01), Anderson et al.
patent: 2006/0286122 (2006-12-01), Kempf et al.
patent: 1680499 (2006-07-01), None
patent: WO 2005/049786 (2005-06-01), None
Dabo et al, Microbial Pathogenesis, 2006, 41:10-20.
Hemsworth et al, European J. Oncology Nursing, 2006, 10:117-127.
Kirby, Infection and Immunity, Dec. 2004, 72/12:7315-7317.
Sood et al, Medical Hypotheses, 1997, 48:511-515.
Wagner et al, International J. Medical Microbiology, 2008, 298:579-590.
Dabo et al, Infection and Immunity, May 2006, 74/5:2513-2521.
Kaiser et al, Cellular Microbiology, 2008, pp. 1-12.
Dehio, Current Opinion in Microbiology, 1999, 2:78-82.
Kempf et al, Trends in Microbiology, Jun. 2002, 10/6:269-275.
Riess et al, Infection and Immunity, Jan. 2007, 75/1:35-43.
Szczesny et al, PLoS Pathogens, Aug. 2008, 4/8:1-12.
Lazar et al, Mol. and Cell. Biol., 1988, 8:1247-1252.
Burgess et al, JCB, 1990, 111:2129-2138.
Kumar et al, PNAS, 1990, 87:1337-1341.
Creighton, In: Proteins, Structures and Molecular Prinicples, 1984, pp. 314-315.
Creighton, In: Protein Structure a practical approach, 1990, pp. 184-186.
Nosoh et al, In: Protein Stability and Stabilization Through Protein Engineering, 1991, pp. 198-217.
Bowie et al, Science, 1990, 247/4948:1306-1310.
Chomel et al, Vet. Res., 2009, 40:29, 22 pages.
Greub et al, J. Med. Microbiol., 2002, 51:915-923.
Alsmark, C. (2004) “The louse-borne human pathogenBartonella quintanais a genomic derivative of the zoonotic agentBartonella henselae” PNAS 101:9716-9721.
Blum, W. et al. (1990) “A specific radioimmunoassay for the growth hormone (gh)-dependent somatomedin-binding protein: its use for diagnosis of gh deficiency” Journal of Clinical Endocrinology and Metabolism 70:1292-1298.
Burgess, A. et al. (1998) “Outer membrane proteins ofBartonella henselaeand their interaction with human endothelial cells” Microbial Pathogenesis 25:157-164.
Ikeda, E. et al. (1995) “Hypoxia-induced transcriptional activation and increased mrna stability of vascular endothelial growth factor in c6 glioma cells” The Journal of Biological Chemistry 270:19761- 19766.
Kempf, V. et al. (2001) “Evidence of a leading role for vegf inBartonella henselae-induced endothelial cell proliferations” Cellular Microbiology 3:623-632.
Kibbe, (2000) “Handbook of pharmaceutical Excipients” American Pharmaceutical Association and Pharmaceutical Press, 3rdedition, Textbook.
Raleigh, J. (1998) “Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker” Cancer Research 58:3765-3768.
Regnery, R. et al. (1992) “Characterization of a novelRochalimaeaspecies, r.henselaesp. Nov., isolated from blood of a febrile, human immunodeficiency virus-positive patient” Journal of Clinical Microbiology 30:265-274.
Resto-Ruiz, S. et al. (2002) “Induction of a potential paracrine angiogenic loop between human thp-1 macrophages and human microascular endothelial cells duringBartonella henselaeinfection” Infection and Immunity 70:4564-4570.
Riess, T. et al. (2003) “Rapid and efficient trasposon mutagenesis ofBartonella henselaeby trasposome technology” Gene 313:103-109.
Riess, T. et al. (2004) “Bartonellaadhesion a mediates a proangiogenic host cell response” J. Exp. Med. 200:1267-1278.
Sambrook, J. et al. (2001) “Molecular cloning—a laboratory manual” Cold Spring Harbor Laboratory Press, New York, 3rdEdition, Textbook.
Schulte, R. et al. (2000) “Yersinia enterocoliticainvasion protein triggers il-8 production in epithelial cells via activation of rel p65-p65 homodimers” The FASEB Journal 14:1471-1484.
Alitalo Kari
Anderson Siv
Autenrieth Ingo
Kempf Volkhard
Riess Tanja
Eberhard-Karls Universitat Tubingen Universitatsklinikum
Knobbe Martens Olson & Bear LLP
Minnifield N. M
LandOfFree
Modulation of angiogenesis by Bartonella henselae does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of angiogenesis by Bartonella henselae, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of angiogenesis by Bartonella henselae will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4127335